ALX Oncology Holdings Announces New Data Supporting Phase 1b/2 Clinical Trial For Evoracept In Combination With Jazz Pharmaceutical's Zanidatamab For Patients With Pre-Treated HER2-Positive Metastatic Breast Cancer
ALX Oncology Holdings ALXO | 0.00 | |
Jazz Pharmaceuticals Public Limited Company JAZZ | 0.00 |
The Phase 1b/2 open-label, multi-center clinical trial (NCT05027139) evaluating evorpacept plus zanidatamab included patients with heavily pre-treated HER2-positive mBC (median of five prior HER2-targeted therapies), all of whom had received prior ENHERTU therapy. The primary trial results, presented at the 2024 San Antonio Breast Cancer Symposium (SABCS), demonstrated that the investigational combination generated promising anti-tumor activity and a manageable safety profile.